Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 3Completed 1

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4CNS 1

Conditions

Breast Neoplasms 96Carcinoma, Non-Small-Cell Lung 85Prostatic Neoplasms 75Multiple Myeloma 74Neoplasms 50Leukemia, Myeloid, Acute 44Lymphoma 43Melanoma 42Neoplasm Metastasis 39Ovarian Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Lymphoma, Non-Hodgkin 34Lung Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 32Hematologic Neoplasms 29Colorectal Neoplasms 29Triple Negative Breast Neoplasms 27Hodgkin Disease 24Pancreatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 21Fallopian Tube Neoplasms 21Carcinoma, Renal Cell 21Sarcoma 20Lymphoma, Follicular 20Urinary Bladder Neoplasms 18Recurrence 18Lymphoma, Mantle-Cell 18Head and Neck Neoplasms 18Brain Neoplasms 18

Interventions

Taxes 2Radiotherapy 2Radiation 2Paclitaxel 2trastuzumab biosimilar HLX02 1cixutumumab 1adavosertib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Carboplatin 1CT-P6 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma Of Esophagus × 90 days × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02521285 2026-04-29

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled 35 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT04460937 2026-04-29

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
4 enrolled 9 charts
CNSGastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡